Eris Lifesciences Q3 FY26: Revenue Rs. 807 Cr, PAT Rs. 109 Cr. DBF Growth 10%.
Eris Lifesciences reported Q3 FY26 consolidated revenue of ₹807 crore, up 11% YoY, and adjusted PAT of ₹120 crore, up 38.5% YoY. DBF revenue grew 10% to ₹696 crore. International Business revenue surged 45% to ₹111 crore. The company aims for a Net Debt to EBIDTA ratio below 1.5x by Dec 2026.
The announcement provides a comprehensive update on the company's financial performance, including key revenue and profit figures, segment-wise growth, and strategic initiatives like product launches and debt reduction. This detailed information is material for investors.
The company reported strong year-on-year growth in revenue and profit (PAT), along with positive performance in key segments like Domestic Branded Formulations and International Business. The debt reduction strategy and future growth visibility further contribute to the positive sentiment.
Eris Lifesciences Limited announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3 and 9M FY26). The company reported a consolidated revenue of ₹807 crore for Q3 FY26, an increase of 11% year-on-year, and ₹2,373 crore for 9M FY26, up 8.4% year-on-year. Excluding trade generics, consolidated revenue was ₹807 crore in Q3 FY26 (up 13% YoY) and ₹2,369 crore in 9M FY26 (up 10% YoY).
Consolidated EBITDA stood at ₹282 crore in Q3 FY26, a 13% increase YoY, with an EBITDA margin of 34.9%. For 9M FY26, consolidated EBITDA was ₹847 crore, up 11% YoY, with a margin of 35.7%. Adjusted Profit After Tax (PAT) for Q3 FY26 was ₹120 crore, a significant 38.5% increase YoY, and ₹380 crore for 9M FY26, a 39.3% increase YoY.
The Domestic Branded Formulations (DBF) segment reported revenue of ₹696 crore in Q3 FY26, a 10% YoY growth, and ₹2,106 crore for 9M FY26, also a 10% YoY growth. DBF EBIDTA grew 10% YoY to ₹254 crore in Q3 FY26, with a margin of 36.5%. The company plans to discontinue non-core/tail-end brands, which is expected to impact DBF revenue by ~2% in FY27 but improve operating profits and margins.
The International Business segment showed strong growth, with Q3 FY26 revenue at ₹111 crore, a 45% YoY increase, and EBITDA at ₹33 crore, up 46% YoY. For 9M FY26, revenue was ₹259 crore (11% YoY growth) and EBITDA was ₹81 crore (10% YoY growth). The company projects significant visibility for FY27, expecting revenue of ₹550-600 crore and EBITDA of ₹180-200 crore for the International Business.
Eris Lifesciences is focused on expanding its product portfolio, including new launches like Esaxerenone for hypertension management and readiness for GLP-1 products such as Semaglutide. The company has also made progress in its insulin manufacturing at Bhopal and is on track with its debt reduction strategy, aiming for a Net Debt to TTM EBIDTA ratio of less than 1.5x by December 2026.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.